The MESA Alliance, hosted by our initiative, is engaged in the analysis of a critical issue: how to prevent malaria from coming back into countries that have already eliminated it. Undertaken in support of the World Health Organisation, the work includes three country case studies, a literature review and a landscape analysis of projects. In addition, MESA convened the malaria expert community in a series of fora on pressing challenges related to malaria control and elimination, including the invasive mosquito Anopheles stephensi, mutations that render the parasite undetectable to rapid diagnostic tests, and how to combine malaria interventions to optimise impact. It also co-organised the Malaria Masterclasses in collaboration with the Ifakara Health Institute.
This was an important year for our Unitaid-funded BOHEMIA project. The trial’s field activities in Mozambique were completed with the mass distribution of ivermectin in Mopeia district. BOHEMIA is investigating the potential of this drug to break the cycle of malaria transmission by killing the malaria vectors (Anopheles mosquitoes) that feed on the blood of humans and cattle previously medicated with this endectocide.
The EDCTP-funded ADAM project distributed the first round of mass administration of antimalarials in Chidenguele district, Mozambique. ADAM is collaborating with the National Malaria Control Programme and the Manhiça Health Research Centre in the design and evaluation of strategies for implementing mass drug administration (MDA) and reactive focal drug administration (rFDA) to progress towards malaria elimination, and in writing the national technical guidelines for these two interventions.